Author information from the last article
E-post: kaare.harald.bonaa@ntnu.no
Kaare Harald Bønaa er dr. med., spesialist i indremedisin og i hjertemedisin/invasiv kardiologi, overlege ved Klinikk for hjertemedisin, St. Olavs hospital, faglig leder av Norsk hjerteinfarktregister og professor emeritus ved NTNU.
Articles by Kaare Harald Bønaa
More STEMI patients should receive thrombolytic therapy
- Kaare Harald Bønaa,
- Olav Magne Leiren,
- Bjørn Inge Våga,
- Gunnar Vangberg,
- Ragna Elise Støre Govatsmark,
- Andreas Kristensen,
- Erik Jerome Stene Packer,
- Rune Wiseth,
- Lars Aaberge,
- Sigrun Halvorsen,
- Ole Christian Mjølstad
06.06.2025:
In patients with an ST-elevation myocardial infarction (STEMI) on ECG, the occluded coronary artery must be opened as quickly as possible. This can prevent myocardial damage, complications and death. Many patients in Norway are treated too late. Many STEMI patients do not receive reperfusion therapy...
Health-related quality of life after myocardial infarction
- Ragna Elise Støre Govatsmark,
- Kari Krizak Halle,
- Andrew Malcolm Garratt,
- Kaare Harald Bønaa,
- Veronica Bendiktsen Berge,
- Tove Aminda Hanssen
09.04.2025:
Health outcomes following myocardial infarction are typically measured in terms of mortality, risk of relapse and readmission. The patient perspective, in the form of patient-reported health and quality of life, is also important when planning treatment and care (1–3). Patients who have experienced...
Data quality in the Norwegian Myocardial Infarction Registry
- Ida Almenning Kiel,
- Ragna Elise Støre Govatsmark,
- Veronica Bendiktsen Berge,
- Kari Krizak Halle,
- Stian Lydersen,
- Cecilie Risøe,
- Bjørn Haug,
- Jarle Jortveit,
- Siri Malm,
- Gard F.T. Svingen,
- Miriam Wiksnes,
- Christian Engelsen Berg-Hansen,
- Lars Håvard Nilsen,
- Espen Ellingsen Moe,
- Kaare Harald Bønaa
26.03.2025:
In Norway, 61 national medical quality registries have been established, based on diagnoses, procedures or services (1). The main purpose of these registries is to contribute to better patient treatment (1, 2). They are also used for research and administration. In many medical fields, the national...
Correction: Incidence and case fatality of acute myocardial infarction in Norway 2013–2021
- Kaare Harald Bønaa,
- Kari Krizak Halle,
- Ragna Elise Støre Govatsmark,
- Veronica Bendiktsen Berge,
- Ida Almenning Kiel,
- Gerhard Sulo,
- Rune Kvåle
24.10.2024:
Tidsskr Nor Legeforen 2024; 144. doi: 10.4045/tidsskr.24.0237 The paragraph above Table 1 should say: The number of patients with a first-time infarction event decreased from 14 361 (391/100 000) in 2013 to 11 264 (271/100 000) in 2021, (…) Table 1 should say: All myocardial infarctions in 2021: n...
Incidence and case fatality of acute myocardial infarction in Norway 2013–2021
- Kaare Harald Bønaa,
- Kari Krizak Halle,
- Ragna Elise Støre Govatsmark,
- Veronica Bendiktsen Berge,
- Ida Almenning Kiel,
- Gerhard Sulo,
- Rune Kvåle
10.10.2024:
Over the past 100 years, ischemic heart disease mortality has changed considerably in Norway. In the first half of the last century, mortality steadily increased, except for a marked decrease during World War II (1). Mortality then rose substantially in the post-war years, peaking in the 1970s, and...
Does a history of cardiovascular disease or cancer affect mortality after SARS-CoV-2 infection?
- Rune Kvåle,
- Kaare Harald Bønaa,
- Rachel Forster,
- Kirsten Gravningen,
- Pétur Benedikt Júlíusson,
- Tor Åge Myklebust
29.12.2020:
Cardiovascular disease and cancer have been described as possible risk factors for serious illness and death as a result of COVID-19 (1, 2). In addition to comorbidities, previously published studies have shown that increasing age and male sex are also associated with a greater mortality risk (3–6)...
Treatment of ST-elevation myocardial infarction – an observational study
- Julie Synnøve Arnesen,
- Knut Henrik Strøm,
- Kaare Harald Bønaa,
- Rune Wiseth
18.11.2019:
In myocardial infarction with ST-segment elevation, rapid reperfusion of the occluded coronary artery is important to reduce myocardial damage. The benefit of reperfusion therapy is greatest when it is administered within 2–3 hours of symptom onset (1, 2). In Norway, the European Society of...
Coronary angiography in non-ST-elevation acute myocardial infarction – whom and when?
- Kaare Harald Bønaa,
- Terje Steigen
13.11.2017:
Many patients with non-ST-elevation acute myocardial infarction (NSTEMI) ultimately undergo percutaneous coronary intervention or coronary artery bypass surgery. Both procedures require prior diagnostic coronary angiography. Should all patients with NSTEMI be referred for coronary angiography? And...